Growth OpportunitiesCitius Oncology plans to expand Lymphir's indications to peripheral T cell lymphoma and broader immune oncology, which presents additional growth opportunities.
Market OpportunityLymphir is on track to launch in 1Q25, and the CTCL market is attractive with minimal direct competition, allowing Lymphir to potentially gain rapid market share.
Market ReadinessCitius Oncology has made significant progress with its first year supply produced, rolling out targeted education programs for providers, and working on market access and patient support.